Stockreport

Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA [Yahoo! Finance]

Frequency Electronics, Inc.  (FEIM) 
US:NASDAQ Investor Relations: ir.freqelec.com/home
PDF clinically meaningful improvements in overall survival and progression-free survival versus nab-paclitaxel and gemcitabine NAPOLI 3 represents the first positive Phase [Read more]